Stoke

Stoke Therapeutics develops RNA-based medicines using its TANGO approach to restore protein levels, notably zorevunersen for Dravet syndrome.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2019
Stage of Initial Investment
Series B
Initial Investment Year
2018